All Stories

  1. A biomimetic oral immunotherapy platform for peanut allergy
  2. Chronic spontaneous urticaria remission definition and therapy stepping down: World Allergy Organization position paper
  3. An algorithm for the diagnosis of beta‐lactam allergy, 2024 update
  4. Predictors of biological therapy in severe asthma patients. An ambispective study from the BIOBADALER consortium.
  5. Diagnosis, Pathogenesis and Treatment of Chronic Spontaneous Urticaria
  6. An algorithm for the diagnosis, pathogenesis and treatment of chronic spontaneous urticaria, 2024 update
  7. Biomarkers predicting the controller dose of omalizumab in patients with chronic spontaneous urticaria
  8. Serum Amyloid A as a Potential Biomarker for Disease Activity in Chronic Spontaneous Urticaria
  9. Efficacy and safety of on‐demand versus daily rupatadine in chronic spontaneous urticaria: A randomized trial
  10. Chronic Spontaneous Urticaria: The Role and Relevance of Autoreactivity, Autoimmunity, and Autoallergy
  11. In chronic spontaneous urticaria soluble FcεRI is elevated and linked to atopy and chronic inducible urticaria
  12. Determinants of effective treatment coverage for posttraumatic stress disorder: findings from the World Mental Health Surveys
  13. Unveiling chronic spontaneous urticaria pathophysiology through systems biology
  14. Cost-utility analysis of the UPRIGHT intervention promoting resilience in adolescents
  15. Incidence of mental disorders in the general population aged 1–30 years disaggregated by gender and socioeconomic status
  16. The relationship between air pollution and multimorbidity: Can two birds be killed with the same stone?
  17. Corrigendum to ‘Suicide-related thoughts and behavior and suicide death trends during the COVID-19 in the general population of Catalonia, Spain’ [European Neuropsychopharmacology 56 (2021) 4–12]
  18. The effectiveness of a “EspaiJove.net”- a school-based intervention programme in increasing mental health knowledge, help seeking and reducing stigma attitudes in the adolescent population: a cluster randomised controlled trial
  19. Medical algorithm: Diagnosis and management of histaminergic angioedema
  20. Mental health symptoms 1 year after the COVID-19 outbreak in Spain: The role of pre-existing mental disorders and their type
  21. Angioedema severity and impact on quality of life: Chronic histaminergic angioedema versus chronic spontaneous urticaria
  22. The associations between traumatic experiences and subsequent onset of a substance use disorder: Findings from the World Health Organization World Mental Health surveys
  23. Classification and Treatment of Angioedema without Wheals: A Spanish Delphi Consensus
  24. Health Inequalities by Sexual Orientation: Results from the 2016–2017 Barcelona Health Survey
  25. The Association of Age With Depression, Anxiety, and Posttraumatic Stress Symptoms During the COVID-19 Pandemic in Spain: The Role of Loneliness and Prepandemic Mental Disorder
  26. Clinical and immunological data from chronic urticaria onset after mRNA SARS‐CoV‐2 vaccines
  27. Reliability of a novel electro‐medical device for wheal size measurement in allergy skin testing: An exploratory clinical trial
  28. Consensus on the Definition of Control and Remission in Chronic Urticaria
  29. Increased risks for mental disorders among LGB individuals: cross-national evidence from the World Mental Health Surveys
  30. Determinants of effective treatment coverage for major depressive disorder in the WHO World Mental Health Surveys
  31. Unraveling the Diagnosis of Kiwifruit Allergy: Usefulness of Current Diagnostic Tests
  32. Autoimmune chronic spontaneous urticaria
  33. Urticaria crónica espontánea : abordaje diagnóstico y terapéutico
  34. Validation of a commercial allergen microarray platform for specific immunoglobulin E detection of respiratory and plant food allergens
  35. Biomarkers Commonly Associated with Urticaria Severity Do Not Correlate With Angioedema Activity Scores
  36. [Artículo traducido] Práctica clínica diaria en el manejo de la urticaria crónica en España: resultados del estudio UCREX
  37. Proposal of 0.5 mg of protein/100 g of processed food as threshold for voluntary declaration of food allergen traces in processed food—A first step in an initiative to better inform patients and avoid fatal allergic reactions: A GA²LEN position paper
  38. Validation of novel recipes for masking peanuts in double-blind, placebo-controlled food challenges
  39. High prevalence of obstructive sleep apnea syndrome in Spain’s Stroke Belt
  40. Erratum to "IgE allergy diagnostics and other relevant tests in allergy, a World Allergy Organization position paper" [World Allergy Organ J 13/2 (2020) 100080]
  41. A Comparative Study of Sex Distribution, Autoimmunity, Blood, and Inflammatory Parameters in Chronic Spontaneous Urticaria with Angioedema and Chronic Histaminergic Angioedema
  42. ARADyAL: The Spanish Multidisciplinary Research Network for Allergic Diseases
  43. Role of nanostructures in allergy: Diagnostics, treatments and safety
  44. Approach to Occupational Contact Dermatitis in an Industrialized Region of Spain
  45. Autoimmune Diseases Are Linked to Type IIb Autoimmune Chronic Spontaneous Urticaria
  46. A Specialized Therapeutic Approach to Chronic Urticaria Patient’s Refractory to H1-Antihistamines Improves the Burden of the Disease. The Spanish AWARE Experience
  47. Identification and Characterization of IgE‐Reactive Proteins and a New Allergen (Cic a 1.01) from Chickpea (Cicer arietinum)
  48. Role of nanostructures in allergy: adverse effects, diagnostics, and treatment
  49. IgE allergy diagnostics and other relevant tests in allergy, a World Allergy Organization position paper
  50. Histaminergic angioedema: similarities and differences between isolated angioedema and chronic urticaria with angioedema
  51. Urticaria: Collegium Internationale Allergologicum (CIA) Update 2020
  52. Therapeutic Strategy According to Differences in Response to Omalizumab in Patients With Chronic Spontaneous Urticaria
  53. Negative autoimmunity in a Spanish pediatric cohort suspected of type 1 diabetes, could it be monogenic diabetes?
  54. Biomarkers and clinical characteristics of autoimmune chronic spontaneous urticaria: Results of the PURIST Study
  55. Efficacy and Safety of Omalizumab (Xolair) for Cholinergic Urticaria in Patients Unresponsive to a Double Dose of Antihistamines: A Randomized Mixed Double-Blind and Open-Label Placebo-Controlled Clinical Trial
  56. Adjuvants in Allergen-Specific Immunotherapy: Modulating and Enhancing the Immune Response
  57. Psychometric properties of the Spanish version of the once-daily Urticaria Activity Score (UAS) in patients with chronic spontaneous urticaria managed in clinical practice (the EVALUAS study)
  58. Lifetime and 12‐month treatment for mental disorders and suicidal thoughts and behaviors among first year college students
  59. Mental disorder comorbidity and suicidal thoughts and behaviors in the World Health Organization World Mental Health Surveys International College Student initiative
  60. The role impairment associated with mental disorder risk profiles in the WHO World Mental Health International College Student Initiative
  61. Predicting Chronic Spontaneous Urticaria Symptom Return After Omalizumab Treatment Discontinuation: Exploratory Analysis
  62. DIAGNOSTIC PERFORMANCE OF DIFFERENT METHODS FOR DETECTION OF SENSITIZATION TO PRU P 3 IN SPAIN
  63. Allergic rhinitis severity can be assessed using a visual analogue scale in mild, moderate and severe
  64. Biologics in chronic urticaria
  65. Allergy rhinitis: similarities and differences between children and adults
  66. Oral immunotherapy using polymeric nanoparticles loaded with peanut proteins in a murine model of fatal anaphylaxis
  67. Improvement of the Elevated Tryptase Criterion to Discriminate IgE- From Non–IgE-Mediated Allergic Reactions
  68. Expert opinion: defining response to omalizumab in patients with chronic spontaneous urticaria
  69. Adjuvants for allergy immunotherapeutics
  70. Omalizumab efficacy in cases of chronic spontaneous urticaria is not explained by the inhibition of sera activity in effector cells
  71. Predicting return of chronic idiopathic urticaria symptoms following omalizumab treatment discontinuation: Exploratory analysis of phase III data
  72. Angio-oedema without hives, IgE and omalizumab
  73. Allergic rhinitis severity can be assessed using a visual analogue scale in mild, moderate and severe
  74. Sustained Effect and Clinical Outcomes in Chronic Spontaneous Urticaria in Patients Receiving Omalizumab for Several Years
  75. Allergy rhinitis: similarities and differences between children and adults
  76. Treatment of chronic spontaneous urticaria with an inadequate response to H1-antihistamines: an expert opinion
  77. Estudio de carcinoma medular de tiroides a partir de un caso índice
  78. Induction of tolerance to different types of fish through desensitization with hake
  79. Updosing nonsedating antihistamines in patients with chronic spontaneous urticaria: a systematic review and meta-analysis
  80. Management of chronic spontaneous urticaria in routine clinical practice: A Delphi-method questionnaire among specialists to test agreement with current European guidelines statements
  81. Allergic rhinitis causes loss of smell in children: The OLFAPEDRIAL study
  82. Pros and Cons of Clinical Basophil Testing (BAT)
  83. Basophil activation testing in diagnosis and monitoring of allergic disease – an overview
  84. Valoración de tutores clínicos y estudiantes de medicina respecto a las rotaciones en centros de atención primaria y hospitales
  85. Technical flaws in multiple-choice questions in the access exam to medical specialties (“examen MIR”) in Spain (2009–2013)
  86. Timing and duration of omalizumab response in patients with chronic idiopathic/spontaneous urticaria
  87. Eosinophilic Bronchitis Caused By Exposure to Wheat Flour in the Workplace
  88. Comparable actions of omalizumab on mast cells and basophils
  89. The Incidence of Perioperative Sensitivity Reactions
  90. Lower limb function and 10-year survival in population aged 75 years and older
  91. Validation of The Spanish Version of The Urticaria Activity Score (Uas) and Its Use Over One Week (Uas7)
  92. The clinical utility of basophil activation testing in diagnosis and monitoring of allergic disease
  93. Immunological events in chronic spontaneous urticaria
  94. Profile of omalizumab in the treatment of chronic spontaneous urticaria
  95. The Incidence of Perioperative Hypersensitivity Reactions
  96. Are all new allergens in TRUE Test®essential for a baseline set?
  97. Positive response to omalizumab in patients with acquired idiopathic nonhistaminergic angioedema
  98. Management of urticaria: not too complicated, not too simple
  99. Identification and Characterization of a New Oil Body Fraction Peanut Allergen
  100. Satisfacción de los estudiantes ante una sesión de exploración cardiológica impartida por compañeros entrenados
  101. A Follow-up Study to Monitor Adult Height Among Spanish Children with Growth Hormone Deficiency Who Received Biosimilar Human Recombinant Growth Hormone (Omnitrope®) During a Phase III Clinical Trial
  102. Management of angioedema without urticaria in the emergency department
  103. Nanoparticle based-immunotherapy against allergy
  104. Immunogenicity of Peanut Proteins Containing Poly(Anhydride) Nanoparticles
  105. Perioperative Reactions: Are They So Infrequent?
  106. The usefulness of plasma histamine and different tryptase cut-off points in the diagnosis of peranaesthetic hypersensitivity reactions
  107. Pomegranate (Punica granatum L.) Expresses Several nsLTP Isoforms Characterized by Different Immunoglobulin E-Binding Properties
  108. Analysis of comorbidities and therapeutic approach for allergic rhinitis in a pediatric population in Spain
  109. A Randomized Trial of Cardiopulmonary Resuscitation Training for Medical Students
  110. Efficacy of omalizumab in chronic spontaneous urticaria refractory to conventional therapy: analysis of 110 patients in real-life practice
  111. Bilastine for the treatment of urticaria
  112. Recently introduced foods as new allergenic sources: Sensitisation to Goji berries (Lycium barbarum)
  113. Analysis of the Association Between Food Allergy and Sensitization to Ltp and Profilin
  114. The Absence of Oil Body Proteins in Allergenic Extract Might Be Involved in False-Negative Diagnosis of Some Peanut Allergic Patients
  115. Pru p 3 acts as a strong sensitizer for peanut allergy in Spain
  116. EAACI taskforce position paper: evidence for autoimmune urticaria and proposal for defining diagnostic criteria
  117. Development of poly(anhydride) nanoparticles loaded with peanut proteins: The influence of preparation method on the immunogenic properties
  118. Validation of the modified allergic rhinitis and its impact on asthma (ARIA) severity classification in allergic rhinitis children: the PEDRIAL study
  119. Nuevas formas farmacéuticas para el tratamiento de enfermedades alérgicas
  120. Research needs in allergy: an EAACI position paper, in collaboration with EFA
  121. Nanoparticulate Adjuvants and Delivery Systems for Allergen Immunotherapy
  122. Assessing Degree of Flowering Implicates Multiple <i>Chenopodiaceae/Amaranthaceae</i> Species in Allergy
  123. Can component-based microarray replace fluorescent enzimoimmunoassay in the diagnosis of grass and cypress pollen allergy?
  124. Pharmacokinetic evaluation of levocetirizine
  125. Omalizumab is effective in nonautoimmune urticaria
  126. Identification and quantification of tomato allergens: in vitro characterization of six different varieties
  127. Ara H 9 Is The Main Allergen In Peanut Allergic Patients In The Mediterranean Area Regardless The Symptom Severity
  128. Diagnostic Reliability Of The Component-based Allergen-microarray In Grass, Cypress And Olive Pollens Allergy
  129. Validation of ARIA (Allergic Rhinitis and its Impact on Asthma) classification in a pediatric population: The PEDRIAL study
  130. Distinguishing Male Juvenile Offenders through Personality Traits, Coping Strategies, Feelings of Guilt and Level of Anger
  131. Creating Biomimetic Polymeric Surfaces by Photochemical Attachment and Patterning of Dextran
  132. Serum total tryptase levels are increased in patients with active chronic urticaria
  133. Validation of ARIA duration and severity classifications in Spanish allergic rhinitis patients - The ADRIAL cohort study
  134. Differences In The Immunologic Response To Peanut Allergen Depending Upon The Route, Lipid Content And Peanut Roasting In An Animal Model
  135. In vitro Diagnosis of Anaphylaxis
  136. Evaluation of Treatment Satisfaction in Children with Allergic Disease Treated with an Antihistamine
  137. A novel nanoparticulate adjuvant for immunotherapy with Lolium perenne
  138. Dermatophagoides farinae-specific immunotherapy in atopic dogs with hypersensitivity to multiple allergens: A randomised, double blind, placebo-controlled study
  139. Adult onset Still's disease after first cycle of pemetrexed and gemcitabine for non-small cell lung cancer
  140. Chronic urticaria: do urticaria nonexperts implement treatment guidelines? A survey of adherence to published guidelines by nonexperts
  141. Toxic Epidermal Necrolysis Related to Pemetrexed and Carboplatin with Vitamin B12 and Folic Acid Supplementation for Advanced Non-Small Cell Lung Cancer
  142. Allergen immunotherapy with nanoparticles containing lipopolysaccharide from Brucella ovis
  143. Exercise-induced hypersensitivity syndromes in recreational and competitive athletes: a PRACTALL consensus report (what the general practitioner should know about sports and allergy)
  144. Molecular Diagnosis by Microarray Technology in Polysensitized Atopic Patients
  145. Gantrez® AN nanoparticles as an adjuvant for oral immunotherapy with allergens
  146. Chronic urticaria: What is new, where are we headed
  147. Intradermal immunization with ovalbumin-loaded poly-?-caprolactone microparticles conferred protection in ovalbumin-sensitized allergic mice
  148. Progress and Challenges in the Understanding of Chronic Urticaria
  149. Progress and Challenges in the Understanding of Chronic Urticaria
  150. Usefulness Of Specific Ige Determination To Recombinant Grass Pollen Allergens (cap-feia) In Pollinic Patients
  151. Development of a Novel Vaccine Delivery System Based on Gantrez Nanoparticles
  152. Study of the Role of Basophils in Skin Biopsies of Urticaria
  153. Allergic Contact Dermatitis to Diallyl Disulphide in Spain
  154. Increased responsiveness of basophils of patients with chronic urticaria to sera but hypo-responsiveness to other stimuli
  155. Gantrez® AN nanoparticles do not alter allergenicity of Lollium extract
  156. Comments regarding 'Assessment of histamine-releasing activity of sera from patients with chronic urticaria showing positive autologous skin test on human basophils and mast cells' by Asero et al. M. Ferrer
  157. Urticaria crónica: estudio etiológico prospectivo e importancia del síndrome autoinmune
  158. IL3 effect on basophils histamine release upon stimulation with chronic urticaria sera
  159. Pru p 3 (LTP) content in peach extracts
  160. Siberian hamster: a new indoor source of allergic sensitization and respiratory disease
  161. Secretion of Cytokines, Histamine and Leukotrienes in Chronic Urticaria
  162. Intracellular cytokine IL4 and INF-gamma production in lymphocytes from patients with chronic urticaria
  163. Amiodarone-induced angioedema
  164. Complement dependence of histamine release in chronic urticaria☆☆☆
  165. Importance of food allergy in atopic dermatitis
  166. In vitro antigen‐specific sulphidoleukotriene production in patients allergic to Dermatophagoides pteronyssinus
  167. Comparative studies of functional and binding assays for IgG anti-FcϵRIα (α-subunit) in chronic urticaria☆☆☆★★★
  168. Sulphidoleukotriene and Histamine Releasability in Atopic Patients
  169. 406 Sulphidoleukotriene releasability in pollinic patients
  170. Specific Immunotherapy Induces Changes in Spontaneous IgE Synthesis
  171. Hill activity and anthocyanin levels in Mangifera indica